{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T03:28:36Z","timestamp":1769570916525,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,2]]},"DOI":"10.7759\/cureus.48186","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T04:05:46Z","timestamp":1698984346000},"source":"Crossref","is-referenced-by-count":1,"title":["Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore"],"prefix":"10.7759","author":[{"given":"Behram A","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XiaoJie","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad M","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"National Registry of Diseases Office. Singapore Renal Registry Annual Report 2021. (2021). Accessed. 20 September 2023: https:\/\/www.nrdo.gov.sg\/docs\/librariesprovider3\/default-document-library\/srr-annual-report-2021.pdf?sfvrsn=7bbef4a_0."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone\u00a0disorder (CKD-MBD)","volume":"7","year":"2017","unstructured":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone\u00a0disorder (CKD-MBD). Kidney Int Suppl (2011). 2017, 7.1-59. 10.1016\/j.kisu.2017.04.001","journal-title":"Kidney Int Suppl (2011)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin A","year":"2007","unstructured":"Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007, 71:31-8. 10.1038\/sj.ki.5002009","journal-title":"Kidney Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.18631","article-title":"Second chances to improve ESRD outcomes with a second-generation calcimimetic","volume":"317","author":"Middleton JP","year":"2017","unstructured":"Middleton JP, Wolf M. Second chances to improve ESRD outcomes with a second-generation calcimimetic. JAMA. 2017, 317:139-41. 10.1001\/jama.2016.18631","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19456","article-title":"Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials","volume":"317","author":"Block GA","year":"2017","unstructured":"Block GA, Bushinsky DA, Cunningham J, et al.. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA. 2017, 317:146-55. 10.1001\/jama.2016.19456","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block GA","year":"2017","unstructured":"Block GA, Bushinsky DA, Cheng S, et al.. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA. 2017, 317:156-64. 10.1001\/jama.2016.19468","journal-title":"JAMA"},{"key":"ref7","article-title":"Rapid transition to a telemedicine service at Singapore community dialysis centers during Covid-19","volume":"May","author":"Ngoh LY","year":"2020","unstructured":"Ngoh LY, Wong WK, Leo CC, et al.. Rapid transition to a telemedicine service at Singapore community dialysis centers during Covid-19. NEJM Catalyst. 2020, May:1-11.","journal-title":"NEJM Catalyst"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.47102\/annals-acadmedsg.2020369","article-title":"Impact of telemedicine on hospitalisation and mortality rates in community based haemodialysis centres in Singapore during the COVID-19 pandemic","volume":"49","author":"Singh T","year":"2020","unstructured":"Singh T, Ngoh CL, Wong K, et al.. Impact of telemedicine on hospitalisation and mortality rates in community based haemodialysis centres in Singapore during the COVID-19 pandemic. Ann Acad Med Singap. 2020, 49:756-63. 10.47102\/annals-acadmedsg.2020369","journal-title":"Ann Acad Med Singap"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43114","article-title":"The impact of COVID-19 infection control measures on end-stage renal disease patients in a community hemodialysis setting","volume":"15","author":"Khan BA","year":"2023","unstructured":"Khan BA, Tagore R, Rastogi S, et al.. The impact of COVID-19 infection control measures on end-stage renal disease patients in a community hemodialysis setting. Cureus. 2023, 15:e43114. 10.7759\/cureus.43114","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/singaporemedj.SMJ-2023-036","article-title":"Outcomes and mortality of chronic haemodialysis patients in community-based dialysis centres in Singapore during the COVID-19 pandemic","author":"Teo RZ","year":"2023","unstructured":"Teo RZ, Yan H, Singh T, Khan BA. Outcomes and mortality of chronic haemodialysis patients in community-based dialysis centres in Singapore during the COVID-19 pandemic. Singapore Med J. 2023, 10.4103\/singaporemedj.SMJ-2023-036","journal-title":"Singapore Med J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.69","article-title":"Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease","volume":"82","author":"Torres PA","year":"2012","unstructured":"Torres PA, De Broe M. Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease. Kidney Int. 2012, 82:19-25. 10.1038\/ki.2012.69","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565020-00007","article-title":"Cinacalcet hydrochloride","volume":"65","author":"Barman Balfour JA","year":"2005","unstructured":"Barman Balfour JA, Scott LJ. Cinacalcet hydrochloride. Drugs. 2005, 65:271-81. 10.2165\/00003495-200565020-00007","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07730814","article-title":"The effects of cinacalcet in older and younger patients on hemodialysis: the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial","volume":"10","author":"Parfrey PS","year":"2015","unstructured":"Parfrey PS, Dr\u00fceke TB, Block GA, et al.. The effects of cinacalcet in older and younger patients on hemodialysis: the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Clin J Am Soc Nephrol. 2015, 10:791-9. 10.2215\/CJN.07730814","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014040414","article-title":"Effects of cinacalcet on fracture events in patients receiving hemodialysis: The EVOLVE Trial","volume":"26","author":"Moe SM","year":"2015","unstructured":"Moe SM, Abdalla S, Chertow GM, et al.. Effects of cinacalcet on fracture events in patients receiving hemodialysis: The EVOLVE Trial. J Am Soc Nephrol. 2015, 26:1466-75. 10.1681\/ASN.2014040414","journal-title":"J Am Soc Nephrol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow GM","year":"2012","unstructured":"Chertow GM, Block GA, Correa-Rotter R, et al.. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012, 367:2482-94. 10.1056\/NEJMoa1205624","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2023.03.008","article-title":"Pill-burden and its association with treatment burden among patients with advanced stages of chronic kidney disease","volume":"31","author":"Al-Mansouri A","year":"2023","unstructured":"Al-Mansouri A, Hamad AI, Al-Ali FS, et al.. Pill-burden and its association with treatment burden among patients with advanced stages of chronic kidney disease. Saudi Pharm J. 2023, 31:678-86. 10.1016\/j.jsps.2023.03.008","journal-title":"Saudi Pharm J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1159\/000520028","article-title":"Medication burden and prescribing patterns in patients on hemodialysis in the USA, 2013-2017","volume":"52","author":"Paik JM","year":"2021","unstructured":"Paik JM, Zhuo M, York C, Tsacogianis T, Kim SC, Desai RJ. Medication burden and prescribing patterns in patients on hemodialysis in the USA, 2013-2017. Am J Nephrol. 2021, 52:919-28. 10.1159\/000520028","journal-title":"Am J Nephrol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144119","article-title":"Nonadherence to medication therapy in haemodialysis patients: a systematic review","volume":"10","author":"Ghimire S","year":"2015","unstructured":"Ghimire S, Castelino RL, Lioufas NM, Peterson GM, Zaidi ST. Nonadherence to medication therapy in haemodialysis patients: a systematic review. PLoS One. 2015, 10:e0144119. 10.1371\/journal.pone.0144119","journal-title":"PLoS One"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/200785-real-world-experience-of-using-etelcalcetide-for-secondary-hyperparathyroidism-in-community-based-hemodialysis-centers-in-singapore","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:09:58Z","timestamp":1707509398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/200785-real-world-experience-of-using-etelcalcetide-for-secondary-hyperparathyroidism-in-community-based-hemodialysis-centers-in-singapore"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.48186","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,2]]}}}